Ciglitazone

Overview

Ciglitazone is a potent and selective PPARγ agonist ( EC 50 =3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-W011220
• CAS No.: 74772-77-3
• Molecular Formula: C18H23NO3S
• Molecular Weight: 333.45
• Purity: 99.74%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution
• Availability: In-stock

Source

Original product source